Active Pharmaceutical Ingredient Market, By Type (Generic and Branded), By Business Mode (Captive API and Merchant API), By Synthesis Type (Synthetic and Biotech), By Application (Cardiology, Pulmonology, Oncology, Ophthalmology, Neurology, and Orthopedic), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

An active pharmaceutical ingredient (API) is a drug or mixture of drugs applicable in a finished pharmaceutical product (FPP). API is a biologically active ingredient within the drug product intended for the treatment, diagnosis, or prevention of a disease. It is the definite component liable for the desired effect it has on the subject using it. The Active pharmaceutical ingredients (API) market accounted for US$ 164.89 billion in 2020 and is estimated to be US$ 339.08 billion by 2030 and is anticipated to register a CAGR of 7.5%.

Rising prevalence of infectious diseases

Rising prevalence of infectious diseases, cardiovascular conditions, and other chronic disorders among individuals globally is the major factor driving growth of the global market. In addition, due to rising prevalence of cancer, several manufacturers are focusing on development of highly potent APIs (HPAPI) and specialty APIs, thus boosting growth of the global market. According to data published by World health organization, cancer is the second leading cause of death globally and is projected to account for 9.6 million deaths in 2018.

Furthermore, large numbers of drugs are in the pipeline to develop treatments for cancer, autoimmune disorder, and metabolic diseases. Increasing healthcare expenditure and rising geriatric population in developing countries are expected to enhance growth of the target market over the forecast period. However, increasing penetration of counterfeit drugs and unfavorable drug price control policies across various countries is expected to hamper growth of the active pharmaceutical ingredients (API) market over the forecast period. Nevertheless, increasing demand toward the development of complex APIs used in novel formulations, targeting niche therapeutic areas is the major trend observed for the growth of the target market.

The active pharmaceutical ingredients (API) market is segmented based of type, business mode, synthetic type, application, and region.

Based on type, the active pharmaceutical ingredients (API) market is segmented into generic and branded. On the basis of business model, the global market is segmented into captive API and merchant API. On the basis of synthesis type, the global market is bifurcated into synthetic and biotech. Biotech synthesis type segment held the highest market share, owing to high demand for protein-based therapeutics and increasing focus of manufacturers toward biological drugs. Based on application, the target market is classified into Cardiology, Pulmonology, Oncology, Ophthalmology, Neurology, and Orthopedic. Cardiology application segment accounts for the highest growth due to increasing prevalence rate and high amount of product availability.

Based on region the active pharmaceutical ingredients (API) market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2019, North America is anticipated to dominate the global market, followed by Europe. Increasing government focus on generic drugs, coupled with growing incidence of preventable chronic diseases and rising demand for biologics and specialty drugs are the major factor driving growth of the global market in this region. In addition, technological advancements in the manufacturing processes of APIs also boost growth in this region. Asia pacific is projected to register the highest growth over the forecast period. Availability of affordable labor is the major reason industries are setting up the API manufacturing plants in the developing countries such as India and China.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study the active pharmaceutical ingredients (API) market is segmented based of type, business mode, synthetic type, application, and region.

Active Pharmaceutical Ingredient Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

Key players operating in the active pharmaceutical ingredients (API) market includes Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer, Inc., Bristol-Myers Squibb, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline plc, Eli Lilly and Company, AbbVie Inc., and Merck & Co., Inc. Technological advancements in the product as well as in manufacturing process, product launches, and strategic partnerships are some trends witnessed in the global market. For instance, in January 2018, Sterling Pharma Solutions has expanded its presence in the Asia region, owing to increasing Japanese API market. The company aim to provide services such as hazardous chemistry, fluorination, and continuous processing as well as growth in emerging Pharma sector of Japan. In February 2018, ACETO Corporation partnership with Rising Pharmaceuticals and developed Atenolol tablets in range of 25mg, 50mg, and 100mg for hypertension.

• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• Sanofi
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• Pfizer, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• Bristol-Myers Squibb
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• Novartis AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• Boehringer Ingelheim
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• GlaxoSmithKline plc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• Eli Lilly and Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• AbbVie Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• Merck & Co., Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance